On March 4, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced a collaboration agreement with Abbott to support the company's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. The collaboration calls for Abbott to share insights from recent HeartMate 3 trials while also assisting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise. Having the support of Abbott will be a huge advantage for Cadrenal and should ensure that the TECH-LVAD trial is performed with the maximum efficiency as Abbott has a tremendous amount of experience working with this patient population.
